Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer, Express Scripts Clash Over Biosimilar Formulary Placement

Executive Summary

Pfizer VP blames rebate strategies of innovators for difficulty in getting biosimilars on formularies while Express Scripts official says it is all about net cost during House hearing on lowering Rx drug prices.


Related Content

Amgen Resolves Repatha Access Kerfuffle With Express Scripts
FTC Would Get Green Light To Go After Patent Thickets Under Bipartisan Senate Bill
House Judiciary Committee Advances Four Drug Pricing Bills, Although Changes Are Still Likely
HHS Rebate Reform: An Air Of Inevitability In Stakeholder Comments
No More Rebates: HHS Proposed Rule Revises Anti-Kickback Safe Harbor
Pfizer Wants FDA To Stop Sponsor Promos From Implying Biosimilars Are Inferior
Pfizer v. J&J Sets Stage For Biosimilar Showdown Over Exclusive Contracts


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts